Physician profile
Scott Andrew Stone
NPI 1467494690
$11,747.46
in general payments reported to CMS, 2019-2025
67 companies · $3,454 in 2025
The $3,454 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $2,750 · 2021: $1,144 · 2022: $1,064 · 2023: $1,550 · 2024: $1,650 · 2025: $3,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,644 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,643.63 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,000.00 | 2020 | |
| Deciphera Pharmaceuticals INC. | $1,200.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $832.37 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $602.87 | 2023-2025 | Rybrevant, Carvykti, Talvey |
| Merck Sharp & Dohme LLC | $560.74 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $560.10 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $455.85 | 2021-2024 | Ultomiris |
| Daiichi Sankyo INC. | $398.97 | 2021-2025 | Enhertu, Datroway |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Gilead Sciences, INC. | $330.57 | 2021-2025 | Trodelvy |
| Abbvie INC. | $296.48 | 2022-2025 | Venclexta |
| Pfizer INC. | $275.61 | 2019-2025 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $212.79 | 2023-2025 | |
| Genzyme Corporation | $195.67 | 2021-2025 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $186.18 | 2025 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $182.84 | 2023-2025 | Opdivo |
| Blueprint Medicines Corporation | $173.07 | 2022-2024 | Ayvakit |
| Celgene Corporation | $153.47 | 2022-2025 | Reblozyl, Pomalyst |
| Kite Pharma, INC. | $151.99 | 2023-2024 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $141.28 | 2023-2025 | Iclusig, Ninlaro, Alunbrig |
| Eisai INC. | $129.40 | 2023-2025 | |
| Incyte Corporation | $122.11 | 2022-2025 | Monjuvi, Jakafi |
| Jazz Pharmaceuticals INC. | $119.65 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.28 | 2023-2025 | Libtayo, Lynozyfic |
| Emd Serono, INC. | $117.36 | 2022-2025 | Tepmetko, Bavencio |
| Stemline Therapeutics INC. | $106.47 | 2023-2025 | Orserdu, Elzonris |
| Comsort, INC | $100.00 | 2019 | |
| Pharmaessentia USA Corporation | $97.33 | 2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $92.75 | 2023-2025 | Fotivda |
| Sobi, INC | $88.50 | 2023-2025 | |
| Beigene USA, INC. | $86.51 | 2023-2024 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $82.16 | 2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $80.10 | 2023 | Imbruvica, Epkinly |
| Geron Corporation | $72.64 | 2025 | Rytelo |
| Cti Biopharma Corp. | $68.85 | 2023 | Vonjo |
| Tempus Ai, INC | $47.17 | 2024-2025 | Xt Cdx |
| Seagen INC. | $43.00 | 2022-2023 | Tukysa |
| Recordati_rare_diseases_inc. | $41.41 | 2023-2024 | Sylvant |
| Exelixis INC. | $40.92 | 2022-2025 | Cabometyx |
| Servier Pharmaceuticals LLC | $39.36 | 2023-2024 | |
| Genentech USA, INC. | $39.36 | 2022-2023 | Phesgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.75 | 2024-2025 | Gilotrif |
| Amgen INC. | $38.04 | 2022 | |
| Caris Mpi, INC. | $34.11 | 2025 | Mi Cancer Seek |
| Array Biopharma INC | $33.86 | 2025 | Braftovi, Mektovi, Xalkori |
| Lilly USA, LLC | $25.22 | 2025 | Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $24.98 | 2023 | Krazati |
| Acrotech Biopharma INC. | $23.94 | 2022 | |
| Legend Biotech USA INC. | $23.12 | 2024 | |
| Rigel Pharmaceuticals, INC. | $22.02 | 2023 | Tavalisse, Rezlidhia |
| Adc Therapeutics America, INC. | $21.86 | 2025 | |
| Ge Healthcare | $20.97 | 2022 | |
| Apellis Pharmaceuticals, INC. | $20.88 | 2025 | Empaveli |
| Iovance Biotherapeutics, INC. | $20.02 | 2024 | Amtagvi |
| Taiho Oncology, INC. | $19.81 | 2025 | |
| Medtronic USA, INC. | $19.77 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.27 | 2025 | |
| Glaxosmithkline, LLC. | $18.31 | 2023 | |
| Kyowa Kirin, INC. | $17.17 | 2023 | Poteligeo |
| Beone Medicines USA, INC. | $15.54 | 2025 | Tevimbra |
| Alnylam Pharmaceuticals INC. | $15.29 | 2025 | Givlaari |
| Blue Earth Diagnostics | $15.25 | 2021 | |
| Puma Biotechnology, INC. | $14.10 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.